Navigation Links
American Oriental Bioengineering Reports Third Quarter 2008 Financial Results
Date:11/10/2008

-- Revenue Increased 62% to $70.6 Million in 3Q08 --

-- 3Q08 Net Income Increased 38% to $16.5 Million --

-- 3Q08 Diluted EPS $0.21 versus 3Q07 Diluted EPS $0.16 --

NEW YORK, Nov. 10 /Xinhua-PRNewswire-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products in China, today announced financial results for the quarter ended September 30, 2008.

Financial Results

Revenue in the third quarter of 2008 increased 62% year over year to $70.6 million from $43.5 million, reflecting a continued increase in demand for the Company's OTC and prescription pharmaceutical products. Revenue from pharmaceutical products increased 75% to $62.1 million from $35.5 million in the third quarter of 2007. Revenue from OTC pharmaceutical products increased 91% to $37.8 million from $19.8 million in the prior year's third quarter, reflecting continued recognition of the Company's new products supported by effective marketing campaigns. Sales generated by CCXA and Boke, which were not subsidiaries in the third quarter of 2007, were major contributors to the increase in OTC sales and generated a combined $17.1 million of revenue during the third quarter of 2008. Strong sales of the Jinji series and Jinji Yimucao products also contributed to the increase in OTC revenue during the third quarter of 2008. Prescription pharmaceutical products generated $24.3 million in revenue during the third quarter of 2008, a 55% year over year increase. Prescription pharmaceutical sales increasingly reflect contributions from the Company's diversifying product portfolio, including recently launched CCXA prescription products, as well as from existing products. Expanding rural market coverage also drove prescription pharmaceutical revenue performance during the third quarter of 2008. Nutraceutical product revenue increased approximately 6% to $8.5 million in the third quarter of 2008 from $8.0 million in the prior year's period, and decreased as a percentage of total revenue to approximately 12% versus 18% in the comparable period. The increase in Nutraceutical revenue was mainly attributed to the increase in sales of peptide tablets and peptide powder. The Company continues to focus on selling and marketing higher growth pharmaceutical products.

Gross profit in the third quarter of 2008 increased 54% to $47.2 million from $30.7 million in the third quarter of 2007. Gross margin was approximately 66.9%, compared to 70.5% in the prior year's period, reflecting the integration of CCXA and a shift in product mix.

For the third quarter of 2008, operating expenses increased 52% to $25.3 million from $16.7 million in the comparable period of 2007. The increase in operating expenses was primarily due to increases in sales and marketing expenses, as well as additional depreciation and amortization costs due to the Boke and CCXA acquisitions. Income from operations in the third quarter of 2008 increased 56% to $21.8 million from $14.0 million in the third quarter of 2007, while operating margin was 31%, compared to 32% in the third quarter of the prior year.

Net income for the third quarter of 2008 increased 38% to $16.5 million, or $0.21 per diluted share, compared to $11.9 million, or $0.16 per diluted share, in the prior year's period. Diluted share count in the third quarter of 2008 was 85.4 million, compared to 75.3 million in the third quarter of 2007.

Mr. Tony Liu, Chairman and Chief Executive Officer of American Oriental Bioengineering, commented, "We are very pleased with our financial performance in the third quarter of 2008, which demonstrates continued growth across all of our product categories. We are also extremely well-capitalized versus competitors, with over $220 million of cash and operating cash flow up 80% year over year. Lastly, our third quarter results support our confidence in our brand strength, expansion into rural markets, and unique positioning as a leading consolidator in China's healthcare space."

Mr. Liu concluded, "Today we are increasing our full year 2008 revenue expectation to at least $250 million, up from prior guidance of $245 million. We are reiterating our full year 2008 net income expectation of $62 million, which excludes convertible note interest expense for the second half of 2008, and also excludes any contributions from Nuo Hua and GHK acquisitions. These recently closed acquisitions should create several exciting opportunities for our Company including enhanced distribution reach in strategic areas like hospital pharmacies, new product development and expertise bringing new products to market in the future."

Conference Call

The Company will hold a conference call at 8:00 am ET on November 10, 2008 to discuss its fiscal third quarter 2008 results. Listeners may access the call by dialing 1-866-578-5801 or 1-617-213-8058 for international callers, access code: 73013671. A webcast will also be available through AOBO's website at http://www.bioaobo.com . A replay of the call will be available through November 17, 2008. Listeners may access the replay by dialing 1-888- 286-8010 or 1-617-801-6888 for international callers, access code: 59642931.

About American Oriental Bioengineering Inc.

American Oriental Bioengineering Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products in China.

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-Q for the quarter ended September 30, 2008, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

ASSETS

SEPTEMBER 30, DECEMBER 31,

2008 2007

UNAUDITED

CURRENT ASSETS

Cash and cash equivalents $219,727,043 $166,410,075

Accounts receivable, net of reserve

of $224,333 and $302,270 at

September 30, 2008 and December 31,

2007, respectively 24,556,175 16,494,619

Inventories, net 17,251,005 12,264,536

Advances to suppliers 1,467,388 4,309,352

Notes receivable 589,725 2,259,616

Refundable deposit 6,386,418 --

Deferred tax assets 529,813 --

Other current assets 615,765 5,134,118

Total Current Assets 271,123,332 206,872,316

LONG-TERM ASSETS

Plant and equipment, net 70,082,061 48,496,760

Land use rights, net 63,883,307 46,310,240

Deposit for long-term assets 23,565,407 --

Construction-in-progress 446,203 755,614

Other intangible assets, net 24,968,293 26,972,166

Goodwill 22,566,768 22,566,768

Investments in and advances to equity

investments 21,479,515 242,551

Deferred tax assets 1,344,484 1,498,481

Unamortized financing cost 4,448,056 --

Total Long-Term Assets 232,784,094 146,842,580

TOTAL ASSETS $503,907,426 $353,714,896

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

LIABILITIES AND SHAREHOLDERS' EQUITY

SEPTEMBER 30, DECEMBER 31,

2008 2007

UNAUDITED

CURRENT LIABILITIES

Accounts payable $4,788,336 $3,436,352

Other payables and accrued expenses 12,679,625 7,786,157

Taxes payable 4,485,151 2,843,719

Short-term bank loans 6,710,332 6,289,222

Current portion of long-term bank

loans 2,966,016 2,374,565

Other liabilities 2,263,080 3,621,030

Deferred tax liabilities 680,544 109,733

Total Current

Liabilities 34,573,084 26,460,778

LONG-TERM LIABILITIES

Long-term bank loans, net of current

portion 818,058 1,263,483

Long-term notes payable 297,390 286,365

Deferred tax liabilities 16,390,430 12,621,180

Convertible Note 115,000,000 --

Total Long-Term

Liabilities 132,505,878 14,171,028

TOTAL LIABILITIES 167,078,962 40,631,806

COMMITMENTS

SHAREHOLDERS' EQUITY

Preferred stock, $0.001 par value;

2,000,000 shares authorized;

1,000,000 shares issued and

outstanding at September 30, 2008

and December 31, 2007, respectively 1,000 1,000

Common stock, $0.001 par value;

150,000,000 shares authorized;

78,249,264 and 77,991,935 shares

issued and outstanding at September

30, 2008 and December 31, 2007,

respectively 78,249 77,992

Common stock to be issued 279,332 1,611,333

Prepaid forward repurchase contract (29,998,616) --

Additional paid-in capital 195,500,513 193,007,987

Retained earnings (the restricted

portion of retained earnings is

$15,910,685 at September 30, 2008

and December 31, 2007, respectively) 141,882,532 102,117,792

Accumulated other comprehensive

income 29,085,454 16,266,986

Total Shareholders'

Equity 336,828,464 313,083,090

TOTAL LIABILITIES AND

SHAREHOLDERS' EQUITY $503,907,426 $353,714,896 AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (UNAUDITED)

THREE MONTHS ENDED NINE MONTHS ENDED

SEPTEMBER 30, SEPTEMBER 30,

2008 2007 2008 2007

REVENUES $70,593,949 $43,514,049 $168,372,552 $103,062,573

COST OF GOODS

SOLD 23,402,407 12,833,252 54,808,490 31,048,916

GROSS PROFIT 47,191,542 30,680,797 113,564,062 72,013,657

Selling and

marketing 9,938,877 5,644,776 22,656,477 12,210,509

Advertising 9,913,728 6,934,160 21,760,300 16,150,754

General and

administrative 4,467,638 3,742,364 13,633,595 9,234,426

Depreciation

and

amortization 1,024,436 377,856 3,012,107 1,054,128

Total

operating

expenses 25,344,679 16,699,156 61,062,479 38,649,817

INCOME FROM

OPERATIONS 21,846,863 13,981,641 52,501,583 33,363,840

EQUITY IN

EARNINGS

(LOSS) FROM

UNCONSOLIDATED

ENTITIES 49,417 3,953 (591,650) 14,848

INTEREST INCOME

(EXPENSE), NET (1,143,013) 360,365 (1,156,782) 375,604

OTHER INCOME

(EXPENSE), NET 91,986 (16,144) (264,515) 118,436

INCOME BEFORE

INCOME TAXES 20,845,253 14,329,815 50,488,636 33,872,728

INCOME TAXES 4,362,334 2,386,189 10,723,896 5,846,543

NET INCOME 16,482,919 11,943,626 39,764,740 28,026,185

OTHER

COMPREHENSIVE

INCOME

Foreign

currency

translation

gain, net of

tax 729,272 1,992,992 12,818,468 4,884,314

TOTAL OTHER

COMPREHENSIVE

INCOME, NET OF

TAX 729,272 1,992,992 12,818,468 4,884,314

COMPREHENSIVE

INCOME $17,212,191 $13,936,618 52,583,208 $32,910,499

NET INCOME PER

SHARE

BASIC $0.22 $0.16 0.52 $0.41

DILUTED $0.21 $0.16 0.50 $0.40

WEIGHTED

AVERAGE NUMBER

OF SHARES

OUTSTANDING

BASIC 75,101,869 74,379,650 77,164,602 68,012,018

DILUTED 85,417,621 75,331,015 80,553,647 69,234,193


'/>"/>
SOURCE American Oriental Bioengineering Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. SportCoatings; The North American Booster Club Association (NABCA); the Coatings Specialist Group New Booster Program Goes High Tech With Invisible Antimicrobial Defense
3. American Stock Exchange Lists The Common Stock Of Neuralstem, Inc.
4. American Oriental Bioengineering Announces Participation in September Investor Conferences
5. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
6. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
7. Tips from the Journals of the American Society for Microbiology
8. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
9. Americas Heartland Launches Third Season Highlighting Contributions of American Farmers and Ranchers
10. American and European Parkinsons Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot
11. AUDIO from Medialink and Pfizer: Hispanic Heritage Month Reminds Us Increasing Numbers of Hispanic-Americans Do Not Have Health Insurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... WEDI, the nation’s leading authority on the ... Charles W. Stellar has been named by the WEDI Board of Directors as WEDI’s ... an executive leader with more than 35 years of experience in healthcare, association management ...
(Date:5/24/2016)... Worcester, Mass. (PRWEB) , ... May 24, 2016 ... ... including heart attacks, diabetes, and traumatic injuries, will be accelerated by research at ... skin cells into engines of wound healing and tissue regeneration. , The novel ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... ... a newly re-branded identity. The new Media Cybernetics corporate branding reflects a results-driven ... of imaging and image analysis. The re-branding components include a crisp, refreshed logo ...
(Date:5/23/2016)... WARSAW, Ind. , May 23, 2016 Zimmer ... in musculoskeletal healthcare, today announced that its Board of Directors ... stockholders for the second quarter of 2016. ... on or about July 29, 2016 to stockholders of record ... Future declarations of dividends are subject to approval of the ...
Breaking Biology Technology:
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
(Date:4/19/2016)... 20, 2016 The new GEZE ... compact web-based "all-in-one" system solution for all door components. ... or the door interface with integration authorization management system, ... systems. The minimal dimensions of the access control and ... building installations offer considerable freedom of design with regard ...
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
Breaking Biology News(10 mins):